Mural Oncology PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Mural Oncology's 10-K filing highlights financial uncertainties regarding its ability to continue as a going concern, despite ongoing clinical trials for its lead product candidate, nemvaleukin alfa, and other pipeline developments.
Mural Oncology's 10-K filing outlines its capital structure, share issuance policies, dividend procedures, and compliance with Irish and U.S. securities regulations.